{"id":469533,"date":"2021-04-01T08:03:23","date_gmt":"2021-04-01T12:03:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469533"},"modified":"2021-04-01T08:03:23","modified_gmt":"2021-04-01T12:03:23","slug":"vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/","title":{"rendered":"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline"},"content":{"rendered":"
\n

PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC),\u00a0a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced\u00a0the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB.<\/p>\n

\u201cThe Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,\u201d said\u00a0Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. \u201cTheir collective expertise aligns with the advancement of our diversified oncology pipeline and will be critical as we expand our research and development efforts and prepare to launch Phase 1b studies of VIP152, our highly selective and potent CDK9 inhibitor, in Myc-driven hematologic malignancies and solid tumors, as well as relapsed\/refractory chronic lymphocytic leukemia.\u201d<\/p>\n

\u201cI am delighted to join Vincerx\u2019s SAB along with my esteemed colleagues,\u201d said John C. Byrd, M.D., Chairman of the Vincerx Scientific Advisory Board. \u201cVincerx has a compelling pipeline of potentially transformative oncology therapies and I look forward to working with this team of clinicians, translational researchers, clinical trial experts and oncology pioneers to guide the clinical development and strategy at Vincerx.\u201d<\/p>\n

Vincerx\u2019s SAB is comprised of:<\/p>\n

\n John C. Byrd, M.D. – Chairman<\/strong>
\n
Dr. Byrd is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State\u2019s Comprehensive Cancer Center \u2013 James Cancer Hospital and Solove Research Institute, where he serves as Senior Advisor for Cancer Experimental Therapeutics. He is a Distinguished University Professor of Medicine and Medicinal Chemistry and holds the D. Warren Brown Chair in Leukemia Research. Dr. Byrd is also the Chief Medical Officer for the Beat AML trial. Dr. Byrd received his medical degree from the University of Arkansas for Medical Sciences. His education continued in hematology and oncology at Walter Reed Army Medical Center and Johns Hopkins University before moving to Columbus to join the faculty at Ohio State.<\/p>\n

\n Howard A. \u201cSkip\u201d Burris III, M.D., FASCO, FACP<\/strong>
\n
Dr. Burris serves as President\u00a0and Chief Medical Officer\u00a0of Sarah Cannon, as well as the Executive Director, drug development for Sarah Cannon Research Institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology. Dr.\u00a0Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. He also served as the\u00a0Director of\u00a0Clinical\u00a0Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the U.S. Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor. \u00a0<\/p>\n

\n Gerard Evan, Ph.D.<\/strong>
\n
Dr. Evan is the Sir William Dunn Professor and Head of Biochemistry at the University of Cambridge. Prior to Cambridge, he was the Gerson and Barbara Bass Bakar Distinguished Professor of Cancer Research at the University of California San Francisco (UCSF). Earlier in his career, he was at the Imperial Cancer Research Fund Laboratories in London and elected to the Royal Society\u2019s Napier Research Professorship. Dr. Evan studied Biochemistry at Oxford, earned his Ph.D. at the MRC Laboratory of Molecular Biology in Cambridge, and completed post-doctoral studies in the laboratory of Mike Bishop at UCSF, followed by a return to Cambridge as a research fellow at Downing College. Dr. Evan was elected to EMBO in 1996, the UK Academy of Medical Sciences in 1999, the Royal Society in 2004, the European Academy of Sciences in 2006, the European Academy of Cancer Sciences in 2013, and the Academy of the American Association for Cancer Research in 2019.<\/p>\n

\n Ian W. Flinn, M.D., Ph.D.<\/strong>
\n
Dr. Flinn is an internationally recognized clinical investigator whose research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia. This research includes first in human to Phase 3 trials with novel approaches such as immune effector cell therapies, inhibitors of the B cell receptor pathway, and BCL-2 inhibitors amongst others. He is an author of approximately 200 articles in journals, such as the New England Journal of Medicine, Lancet, Journal of Clinical Oncology<\/em>, and Blood<\/em>. Dr. Flinn joined Tennessee Oncology and Sarah Cannon in 2006 and serves as Director of Lymphoma Research. In his role, he oversees lymphoma research throughout Sarah Cannon and its affiliates.\u00a0Dr. Flinn also serves as the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology.<\/p>\n

\n Andre Goy, M.D., M.S.<\/strong>
\n
Dr. Goy is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin\u2019s disease, non-Hodgkin\u2019s lymphoma including aggressive lymphoma and mantle cell lymphoma, and HIV-associated lymphoma. As Physician in Chief for Hackensack Meridian Health Oncology Services and Chairman of John Theurer Cancer Center at Hackensack University Medical Center as well as Founding Chair of Oncology at the Hackensack Meridian Health School of Medicine, he leads New Jersey\u2019s largest program for research, treatment and management of lymphoma. He is also Professor of Medicine at Georgetown University in Washington, DC. Dr. Goy has trained and\/or worked at some of the world\u2019s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute.<\/p>\n

\n Rosa Lapalombella, Ph.D.<\/strong>
\n
Dr. Lapalombella, Assistant Professor at The Ohio State University, has a strong history of translational medical research. Dr. Lapalombella earned her Ph.D. from the University of Bologna, Italy, and subsequently focused on translational research for hematologic cancers, especially leukemia, and conducted her postdoctoral training in the laboratory of John Byrd, M.D. at The Ohio State University. Prior to her current appointment, she completed four years of post-doctoral training, followed by two-year appointments as a Research Scientist with PI status and then served as a Research Assistant Professor. Her two major areas of research interest are epigenetic alterations of cancer cells and development of experimental therapeutics for hematologic disease.<\/p>\n

\n Anthony W. Tolcher, M.D., FRCPS(C)<\/strong>
\n , FACP<\/strong>
\n
Dr. Tolcher is CEO and Founder of NEXT OncologyTM<\/sup>, San Antonio and Austin, Texas, a Phase I group that seeks to transform early clinical trials. Dr. Tolcher served as President and Co-Founder of START LLC from 2009-2018, one of the world\u2019s largest Clinical Phase I and early drug development operations in cancer medicine with 5 locations in San Antonio, Texas; Grand Rapids, Michigan; Madrid, Spain; and Shanghai, China. Dr. Tolcher is a medical oncologist who has over 25 years\u2019 experience in early drug development and clinical trials. He is currently the principal investigator on 40 Phase I clinical studies, is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research<\/em>, and Annals of Oncology<\/em>. He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program.<\/p>\n

\n About\u00a0Vincerx Pharma, Inc.<\/strong>
\n
Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx\u2019s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx\u2019s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation\/next-generation antibody-drug conjugate platform. For more information, please visit\u00a0www.vincerx.com<\/strong><\/a>.<\/p>\n

\n Cautionary Statement<\/strong>
\n
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the \u201csafe harbor\u201d created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate\u201d or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to: Vincerx\u2019s business model, pipeline, strategy, timeline and product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.<\/p>\n

Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of the COVID-19 pandemic; risks associated with preclinical or clinical development conducted prior to Vincerx\u2019s in-licensing; failure to realize the anticipated benefits of the business combination with LifeSci Acquisition Corp.; failure to realize the benefits of Vincerx\u2019s license agreement with Bayer; risks related to the rollout of Vincerx\u2019s business and the timing of expected business milestones; changes in the assumptions underlying Vincerx\u2019s expectations regarding its future business or business model; Vincerx\u2019s ability to develop and commercialize product candidates; the availability and uses of capital; the effects of competition on Vincerx\u2019s future business; and the risks and uncertainties set forth in Forms 10-K, 10-Q and 8-K filed with or furnished to the\u00a0SEC\u00a0from time to time by Vincerx. Forward -looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.<\/p>\n

\n Contacts<\/strong>
\n
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC),\u00a0a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced\u00a0the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB. \u201cThe Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,\u201d said\u00a0Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. \u201cTheir collective expertise aligns with the advancement of our diversified oncology pipeline and will be critical as we expand our research and development efforts and … <\/p>\n

Continue reading “Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469533","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC),\u00a0a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced\u00a0the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB. \u201cThe Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,\u201d said\u00a0Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. \u201cTheir collective expertise aligns with the advancement of our diversified oncology pipeline and will be critical as we expand our research and development efforts and … Continue reading "Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T12:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline\",\"datePublished\":\"2021-04-01T12:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/\"},\"wordCount\":1716,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/\",\"name\":\"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==\",\"datePublished\":\"2021-04-01T12:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline - Market Newsdesk","og_description":"PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC),\u00a0a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced\u00a0the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB. \u201cThe Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,\u201d said\u00a0Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. \u201cTheir collective expertise aligns with the advancement of our diversified oncology pipeline and will be critical as we expand our research and development efforts and … Continue reading \"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T12:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline","datePublished":"2021-04-01T12:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/"},"wordCount":1716,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/","name":"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==","datePublished":"2021-04-01T12:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTY1NCM0MTAwMjI5IzUwMDA3NDU2Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469533"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469533\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}